Iconovo AB (publ) (ICO.ST) Research

Based in Lund, Sweden, Iconovo AB (publ) focuses on the creation and licensing of advanced inhalation delivery systems. Their product portfolio encompasses a variety of dry powder inhalers, such as the versatile multi-dose ICOres, the capsule-driven ICOcap, the single-use disposable ICOone, and the pre-metered ICOpre. Beyond these standard devices, the company also designs custom inhalation solutions, primarily catering to generic pharmaceutical firms. Iconovo is involved in significant collaborative ventures, including a project with Immune System Regulation AB to develop an inhaled COVID-19 vaccine using their ICOone inhaler, and a partnership with Respiratorius AB (publ) to formulate an inhalation treatment for COPD. The company was established in 2013.

Market snapshot

Symbol
ICO.ST
Price
$1.16
Day change
-0.43%
Market cap
$60.1M
P/E ratio
-1.24x
52-week range
0.906-2.79
Sector
Healthcare
Industry
Medical - Devices
Next earnings
in 16 days

Peer companies

  • Active Biotech AB (publ) (ACTI.ST)
  • Arcoma AB (ARCOMA.ST)
  • Biovica International AB (publ) (BIOVIC-B.ST)
  • Scandinavian Real Heart AB (Publ) (HEART.ST)
  • IDL Diagnostics AB (publ) (IDLDX.ST)
  • Immunovia AB (publ) (IMMNOV.ST)
  • Luxbright AB (publ) (LXB.ST)
  • Pila Pharma AB (publ) (PILA.ST)

Open Iconovo AB (publ) (ICO.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.